- uniQure (QURE, Financial) sees a significant stock surge following a breakthrough therapy designation by the FDA.
- Analysts predict substantial upside potential with an average price target of $36.70.
- Current brokerage recommendations indicate a strong "Outperform" status for QURE.
uniQure (QURE) experienced an impressive surge, with shares climbing nearly 39% in premarket trading. This leap was triggered by the FDA's decision to grant a Breakthrough Therapy designation for AMT-130, a groundbreaking gene therapy aimed at treating Huntington’s disease. This coveted designation is designed to accelerate the development process for treatments addressing serious medical conditions, underscoring the promise evident in the ongoing Phase 1/2 trials.
Wall Street Analysts Forecast
Wall Street analysts are optimistic about uniQure's potential, as evidenced by their one-year price targets. The average price target set by 10 analysts is $36.70, with expectations as high as $70.00 and as low as $13.00. This average target suggests a remarkable upside of 177.06% from the current price of $13.25. For a deeper dive into these estimates, visit the uniQure NV (QURE, Financial) Forecast page.
uniQure NV (QURE, Financial) is receiving favorable evaluations from brokerage firms, with a consensus recommendation rating of 1.8, denoting an "Outperform" status. This rating system ranges from 1 (Strong Buy) to 5 (Sell), indicating robust confidence in the stock's future performance.
On the valuation front, according to GuruFocus estimates, the estimated GF Value for uniQure NV (QURE, Financial) is projected to be $13.56 in one year. This suggests a modest upside of 2.37% from the current price of $13.2461. The GF Value represents GuruFocus' estimate of the stock's fair trading value, derived from historical trading multiples, past business growth, and future performance estimates. Detailed insights are available on the uniQure NV (QURE) Summary page.
